机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China广东省人民医院[2]Guangdong Lung Cancer Institute, Guangdong Province People's Hospital, Southern Medical University, Guangzhou, China广东省人民医院[3]Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China[4]Lung Cancer Department, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China[5]Department of Oncology, First Affiliated Hospital of Zhengzhou University, Zhengzhou, China[6]Second Affiliated Hospital of Nanchang University, Nanchang, China[7]Shanxi Cancer Hospital, Taiyuan, China[8]Department of Otolaryngology-Head and Neck Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China临床科室耳鼻喉科河北医科大学第四医院[9]Department of Phase I Clinical Trial Unit, The Fourth Hospital of Hebei Medical University, Shijiahuang, Hebei Province, China河北医科大学第四医院[10]The First Affiliated Hospital/School of Clinical Medicine Guangdong Pharmaceutical University, Guangzhou, China[11]Thoracic Medicine Department 1, Hunan Cancer Hospital, the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China[12]General Hospital of Eastern Theater Command, Respiratory Department, Nanjing, China[13]The First Affiliated Hospital of Xiamen University, Xiamen, China, Xiamen, China[14]Department of Respiratory Disease, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China浙江大学医学院附属第一医院[15]Zhejiang Cancer Hospital, Internal Medicine for Chest Cancer Department, Hangzhou, China浙江省肿瘤医院[16]Tangdu Hospital, The Fourth Military Medical University, Xi'an, China[17]Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属协和医院[18]Department of Thoracic Oncology, Affiliated Hospital of Guizhou Medical University, and Guizhou Cancer Hospital, Guiyang, PR China[19]Teaching and Research Section, Guiyang, China[20]Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., Chengdu, Sichuan, China
第一作者机构：[1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, China
推荐引用方式(GB/T 7714)：
Zhou Qing,Wu Yi-Long,Zheng Xiangqian,et al.A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41(16):
APA：
Zhou, Qing,Wu, Yi-Long,Zheng, Xiangqian,Li, Dapeng,Huang, Dingzhi...&Ge, Junyou.(2023).A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors.JOURNAL OF CLINICAL ONCOLOGY,41,(16)
MLA：
Zhou, Qing,et al."A phase I study of KL590586, a next-generation selective RET inhibitor, in patients with RET-altered solid tumors".JOURNAL OF CLINICAL ONCOLOGY 41..16(2023)
医学